Cantor Fitzgerald sees Aurinia Pharmaceuticals doubling

|About: Aurinia Pharmaceuticals Inc. (AUPH)|By:, SA News Editor

Aurinia Pharmaceuticals (AUPH +2.6%) stands "well-positioned" in late-stage development of its active lupus nephritis drug treatment, according to Cantor Fitzgerald.

"Voclosporin has generated potent efficacy, as measured by durable complete remission rates, without unwanted liabilities such as nephrotoxicity, increased risk of drug-induced diabetes, and/or unacceptable risk of infection," writes analyst Elemer Piros.

The firm assigns an Overweight rating and $14 price target to Aurinia.